3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
113
Urinary Bladder Neoplasms
56
Carcinoma, Non-Small-Cell Lung
52
Cholangiocarcinoma
33
Biliary Tract Neoplasms
32
Neoplasm Metastasis
30
Ovarian Neoplasms
27
Lymphoma, Large B-Cell, Diffuse
26
Breast Neoplasms
25
Lung Neoplasms
24
Neoplasms
23
Carcinoma, Transitional Cell
23
Triple Negative Breast Neoplasms
22
Nasopharyngeal Carcinoma
21
Colorectal Neoplasms
20
Recurrence
17
Non-Muscle Invasive Bladder Neoplasms
16
Gallbladder Neoplasms
15
Fallopian Tube Neoplasms
15
Sarcoma
13
Bile Duct Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Hodgkin Disease
10
Lymphoma
9
Uterine Cervical Neoplasms
8
Adenocarcinoma
8
Stomach Neoplasms
7
Lymphoma, Non-Hodgkin
7
Endometrial Neoplasms
7
Nasopharyngeal Neoplasms
6
Interventions
toripalimab
2
zanidatamab
1
tislelizumab
1
disitamab vedotin
1
Probiotics
1
Gemcitabine
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscle Invasive Bladder Cancer (MIBC)
×
Gemcitabine
×
1 year
×
Clear all
NCT07296705
2025-12-22
HARBOR
Fujian Medical University Union Hospital
Phase 2
Recruiting
25 enrolled